Clinical Ophthalmology (Oct 2022)
OC-01 (Varenicline Solution) Nasal Spray Demonstrates Consistency of Effect Regardless of Age, Race, Ethnicity, and Artificial Tear Use
Abstract
Alice T Epitropoulos,1,2 Sheraz M Daya,3 Cynthia Matossian,4 Alan G Kabat,5,6 Gretchen Blemker,5 Kristen Striffler,5 Laura Hendrix,5 Marian Macsai,5 Andrea Gibson5 1Ophthalmic Surgeons & Consultants of Ohio, the Eye Center of Columbus, Columbus, OH, USA; 2Department of Ophthalmology, the Ohio State University Wexner Medical Center, Columbus, OH, USA; 3Centre for Sight, London, UK; 4Matossian Eye Associates, Pennington, NJ, USA; 5Oyster Point Pharma, Inc, Princeton, NJ, USA; 6Salus University, Elkins Park, PA, USACorrespondence: Andrea Gibson, Oyster Point Pharma, Inc, 202 Carnegie Center, Suite 109, Princeton, NJ, 08540, USA, Tel +1-860-227-1034, Fax +1-856-433-8439, Email [email protected]: To evaluate OC-01 [varenicline solution nasal spray (VNS)] tear production and symptom outcomes in patients with dry eye disease by age, gender, race, ethnicity, and artificial tear use status.Patients and Methods: Adults ≥ 22 years of age diagnosed with dry eye disease, with Ocular Surface Disease Index score ≥ 23, corneal fluorescein staining score ≥ 2 in ≥ 1 region or ≥ 4 for all regions, and baseline Schirmer Test Score (STS) ≤ 10 mm, with no restrictions on eye dryness score (EDS). Efficacy was assessed using integrated data from ONSET-1 and ONSET-2 [vehicle control (VC), n=294; OC-01 VNS 0.03 mg, n=308]. Subgroups included age (≤ 55, 56− 65, > 65 years), gender (male, female), race (White, Black or African American), ethnicity (Hispanic or Latino, Not Hispanic or Latino), and artificial tear use (yes, no). Analysis of covariance models, with the covariates treatment, study site, and baseline severity measures, were used to calculate treatment−VC differences. Consistency of effect among subgroups was evaluated by conducting interaction tests.Results: Consistency of treatment effect across subgroups was observed for all endpoints, with P value for all treatment−subgroup interaction terms > 0.05. For % of patients with ≥ 10mm improvement in STS and least squares (LS) mean change from baseline in STS and EDS, there was improvement in tear production across demographic group categories. Artificial tear use did not change STS or EDS outcomes with OC-01 VNS.Conclusion: OC-01 VNS improved tear production and patient-reported symptom outcomes across a broad range of patients by age, gender, race, and ethnicity, and regardless of artificial tear use status at baseline. OC-01 VNS demonstrated a consistent benefit across an extensive range of patients with dry eye disease.Keywords: bioactivation, dry eye disease, nicotinic acetylcholine receptor, tear production, varenicline nasal spray
